VALACICLOVIR PROPHYLAXIS OF CYTOMEGALOVIRUS INFECTION AND DISEASE IN RENAL TRANSPLANTATION: AN ECONOMIC EVALUATION

Abstract

Valaciclovir CMV prophylaxis in renal transplantation is a more cost-effective therapy compared with placebo, in the high-risk D+R- patient population. For the R+ group, the incremental cost per case of CMV disease was modest.